Neurocrine Biosciences INC Form 4 insider transactions

Neurocrine Biosciences CEO Kyle Gano exercised stock options and sold 36,400 shares under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Commercial Officer, Eric Benevich, amended a previous filing to correct the number of stock options exercised on November 28, 2025.

Neurocrine Biosciences' Chief Legal Officer, Darin Lippoldt, exercised 3,349 stock options at $35.99 per share, increasing his direct common stock holdings to 46,754 shares.

A Neurocrine Biosciences director exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Legal Officer, Darin Lippoldt, executed a pre-arranged 10b5-1 plan, exercising stock options and selling 4,376 common shares.

Neurocrine Biosciences Director Gary A. Lyons exercised options and sold 15,000 shares of common stock for approximately $152.61 per share under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Commercial Officer, Eric Benevich, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, reported the vesting of 4,426 restricted stock units and the subsequent withholding of 2,248 shares for tax obligations.

Neurocrine Biosciences Director George J. Morrow exercised options and sold 15,000 shares of common stock for approximately $143.37 per share under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences Director William H. Rastetter exercised options and sold 18,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences CEO Kyle Gano reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, gifted 1,470 shares of common stock in a pre-planned transaction.

Neurocrine Biosciences Director Stephen Sherwin reported gifting 1,000 shares of common stock effective September 2, 2025.

A Neurocrine Biosciences director exercised stock options and sold an equivalent number of shares for a significant profit under a pre-arranged trading plan.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, gifted 3,116 shares of common stock in a pre-planned transaction.

Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, exercised stock options and subsequently sold an equal number of shares at a profit under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, exercised stock options and subsequently sold 59,819 shares of common stock for a profit, as part of a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, exercised stock options and subsequently sold an equivalent number of common shares on July 2, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences' Chief Medical Officer, Sanjay Chandru Keswani, has been granted 12,846 Restricted Stock Units and 70,101 stock options as part of his compensation package.

Kevin Charles Gorman, a Director at Neurocrine Biosciences Inc. (NBIX), sold 9,613 shares of common stock for approximately $1.16 million, executed under a Rule 10b5-1 trading plan.

Director William H. Rastetter reported the acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Director Christine Poon reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Kevin Charles Gorman, a director at Neurocrine Biosciences, acquired 6,610 non-qualified stock options on May 21, 2025, at a price of $0.

Director Shalini Sharp reports acquisition and disposal of Neurocrine Biosciences stock and derivative securities.

Director Stephen Sherwin reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Director Richard F. Pops reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Director George J. Morrow reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Director Gary A. Lyons reports acquisition and disposal of Neurocrine Biosciences stock and derivative securities.

Director Leslie V. Norwalk reports acquisition and disposal of Neurocrine Biosciences stock and derivative securities.

Director Johanna Mercier reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.